Loading…
← CockpitCompetitor Analysis › 2395.T Shin Nippon Biomedical Laboratories, Ltd.Open in the cockpit ↗

Shin Nippon Biomedical Laboratories, Ltd.2395.TCompetitor analysis, valuation and peers

Japan · JPY·Industrials›Miscellaneous Commercial Services
Momentum laggard 18
Mkt cap
$297M
US dollars, full cap
Free float
48%
of shares outstanding
$/day
$4.27M
20-day average traded
Fwd P/E
11.5×
forward earnings
ROIC−WACC
-0.5 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
72 days
29 Jan 2027
Close · JPY¥1,157
1D-1.5%
1W-3.7%
1M-17.9%
3M-22.1%
6M-5.2%
YTD-30.8%
1Y-21.8%
ATR %6.1%
52w lowhigh42.3% off high

What Shin Nippon Biomedical Laboratories does

Employees: 1,522

Shin Nippon Biomedical Laboratories at a glance

Size Shin Nippon Biomedical Laboratories (2395.T) is a Japan Industrials company (Miscellaneous Commercial Services) with a market value of $297M, the 1362nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,157 on 18 Nov 2026.

Performance Over six months the shares fell 5.2%, against -27.2% for the median peer and -1.4% for the Japan market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +5.5%); the operating margin is 11.8% (peer median -0.2%).

Valuation It trades at 11.5× forward earnings against a peer median of 15.5× (5th cheapest of 12).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.5 points below its cost of capital (5.0% WACC).

Next results Next results expected around 29 Jan 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 20262395.T 95Peer median 70
Six months, rebased to 100: Shin Nippon Biomedical Laboratories against the median of its 20 peers (local-currency closes).

Shin Nippon Biomedical Laboratories financials

Reported figures in JPY; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue¥35.3B¥32.5B¥32.4B¥26.5B¥25.1B
Revenue growth—0%+23%+5%—
Gross profit¥18.3B¥15.8B¥16.6B¥14.0B¥12.8B
EBITDA¥7.70B¥6.09B¥5.60B¥6.03B¥6.85B
Net income¥5.70B¥4.57B¥4.92B¥5.53B¥6.06B
Free cash flown/a¥3.15B-¥3.82B-¥6.48B-¥836M
Capital expendituren/a¥5.34B¥10.9B¥8.61B¥4.96B
Total debt¥48.8B¥41.4B¥34.6B¥26.3B¥18.9B

Quarterly statements and history in the cockpit →

Shin Nippon Biomedical Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%-10%0%+10%6050693013203005362179300844CTDKNOW301117465803313009614051ELIXREJL-B300948002431277AOBLHCKT3833102395.T6-month return →1-month return →
Up and to the right = strong over both horizons. Shin Nippon Biomedical Laboratories is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%10×20×CTDKNOW30111703314051ELIXREJL-B277AOBLHCKT3833102395.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shin Nippon Biomedical Laboratories is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%CTDKNOW46583009614051ELIXREJL-B002431277AHCKT2395.TGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shin Nippon Biomedical Laboratories is the large dot.

Shin Nippon Biomedical Laboratories competitors and peer comparison

How Shin Nippon Biomedical Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shin Nippon Biomedical Laboratories against its 20 peers (data as of 18 Nov 2026)
Measure2395.TPeer medianRank in peer set
1-month return-17.9%-5.5%2nd lowest of 21
6-month return-5.2%-27.2%6th highest of 21
Distance from 52-week high-42.3%-43.1%11th highest of 21
Revenue growth (TTM)+1.9%+5.5%9th lowest of 21
Operating margin11.8%-0.2%6th highest of 21
Forward P/E11.5×15.5×5th cheapest of 12
Growth the price implies (Req g, 7 yrs)2.8%4.9%5th least demanding of 11
Growth delivered (Del g)+16.6%+13.5%5th highest of 11
Hurdle (Req g minus delivered)-13.8 pp-10.4 pp5th least demanding of 11
ROIC minus cost of capital-0.5 pp-7.1 pp8th highest of 21
EV / EBITDA9.4×8.5×5th most expensive of 12
Net debt / EBITDA3.2×-0.7×most indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shin Nippon Biomedical Laboratories 2395.TJapan$297M-5%+2%12%11.5×2.8%+16.6%
Beijing ZEHO Waterfront Ecological Environment Treatment 605069.SSChina$296M-42%+3%-62%n/an/an/a
Qingdao Richmat Intelligence Technology 301320.SZChina$295M-35%+20%-3%n/an/an/a
Wuhan Nusun Landscape 300536.SZChina$300M-48%+154%-57%n/an/an/a
Jiangsu Recbio Technology 2179.HKHong Kong$302M-39%-82%-25,868%n/an/an/a
Guangzhou S.P.I Design 300844.SZChina$291M-33%-4%-12%n/an/an/a
Corporate Travel Management CTD.AXAustralia$305M-76%+7%6%17.9×9.8%+30.6%
Knowit KNOW.STSweden$306M+25%-6%2%23.6×6.1%+12.1%
Jiayuan Science And Technology 301117.SZChina$286M-64%-41%-67%20.8×n/an/a
Nippon Air Conditioning Services 4658.TJapan$309M-10%+7%7%n/a-0.6%+7.1%
FSE Lifestyle Services 0331.HKHong Kong$309M-2%-3%6%3.9×n/an/a
Hynar Water 300961.SZChina$283M-24%+5%-35%n/a39.1%-8.0%
GMO Financial Gate 4051.TJapan$313M+8%+26%12%20.2×13.0%+26.1%
Elixirr International ELIX.LUnited Kingdom$314M-35%+29%21%7.3×3.8%+37.6%
Rejlers REJL-B.STSweden$314M-13%+6%6%15.8×-2.3%+14.9%
Qingdao Greensum Ecology 300948.SZChina$318M-38%+23%-39%n/an/an/a
Palm Eco-Town Development 002431.SZChina$319M-28%-52%-50%n/a14.2%-16.0%
Globe-Ing 277A.TJapan$323M-21%+31%34%15.2×-5.0%+31.2%
Omni Bridgeway OBL.AXAustralia$323M0%+75%-15%8.8×n/an/a
Hackett HCKTUnited States$325M+31%-8%13%8.5×-0.3%+5.0%
ECOPRO HN 383310.KSSouth Korea$325M-26%-2%13%15.5×n/an/a

Questions

Which companies are Shin Nippon Biomedical Laboratories's closest peers?
The cockpit's peer set: Beijing ZEHO Waterfront Ecological Environment Treatment (605069.SS), Qingdao Richmat Intelligence Technology (301320.SZ), Wuhan Nusun Landscape (300536.SZ), Jiangsu Recbio Technology (2179.HK), Guangzhou S.P.I Design (300844.SZ), Corporate Travel Management (CTD.AX), Knowit (KNOW.ST), Jiayuan Science And Technology (301117.SZ).
Is Shin Nippon Biomedical Laboratories expensive compared with its peers?
On forward p/e it trades at 11.5× against a peer median of 15.5×, 5th cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has Shin Nippon Biomedical Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned -5.2% against -27.2% for the median peer; over one year -21.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.